U.S. Leads Pulmonary Arterial Hypertension Market (PAH) Diagnosed Incident Cases to 2024 Within 7 Major Markets Across the Globe

11 Feb, 2016, 05:00 ET from ReportsnReports

PUNE, India, February 11, 2016 /PRNewswire/ --

ReportsnReports.com adds Pulmonary Arterial Hypertension Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert analysis of disease trends in the 7MM.

The Pulmonary Arterial Hypertension (PAH) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases and diagnosed prevalent cases of PAH, segmented by sex, and age (in 10-year increments beginning at 0 years and ending at =85 years in these markets and is written and developed by Masters- and PhD-level epidemiologists.

Complete report on Pulmonary Arterial Hypertension Market Research to 2024 with 19 market data tables and 16 figures, spread across 72 pages is available at http://www.reportsnreports.com/reports/470866-epicast-report-pulmonary-arterial-hypertension-epidemiology-forecast-to-2024.html .

Pulmonary Arterial Hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death. PAH can be idiopathic, heritable, or associated with different conditions such as connective tissue disease (CTD), congenital heart disease (CHD), human immunodeficiency virus (HIV) infection, and exposure to toxins or drugs. PAH occurs twice as frequently in women as in men.

Epidemiologists forecast an increase in the diagnosed incident cases of PAH in the 7MM, from 1,769 diagnosed incident cases in 2014 to 1,838 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 0.39% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of PAH in the 7MM, with 677 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of PAH, with 74 diagnosed incident cases. Similarly, the diagnosed prevalent cases of PAH in the 7MM are expected to increase from 9,926 diagnosed prevalent cases in 2014 to 10,285 diagnosed prevalent cases in 2024, with an AGR of 0.36% during the forecast period. In 2024, the US will have the highest number of diagnosed prevalent cases of PAH in the 7MM, with 4,325 diagnosed prevalent cases, whereas the UK will have the lowest number of diagnosed prevalent cases of PAH, with 443 diagnosed prevalent cases.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=470866.

Epidemiological forecast for the diagnosed incident and the diagnosed prevalent cases of PAH in the 7MM is supported by age- and sex-specific data. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed incident cases and diagnosed prevalent cases of PAH across the markets. Additionally, GlobalData epidemiologists provided the diagnosed prevalent cases of PAH in each of the 7MM, segmented by the NYHA functional class I-IV, which is an important factor for predicting the prognosis, as well as the need for various clinical and treatment modalities specific to the functional classes, for PAH. GlobalData epidemiologists also provide an additional forecast for the diagnosed incident and diagnosed prevalent cases of PAH, adjusted for the underestimation of registry based forecast. These two different types of forecast strengthen the analysis, and present a comparative assessment of the extent of underestimation when using registry based data, which can be evaluated to provide better insights on the burden of the condition.

Another newly published market research report titled Atherosclerosis - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Atherosclerosis Pipeline Review H2 2015 Research of 258 pages is available at http://www.reportsnreports.com/reports/461984-atherosclerosis-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals market and overall healthcare sector at http://www.reportsnreports.com/market-research/healthcare/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/ 

LinkedIn: https://www.linkedin.com/company/reportsnreports 

Twitter: https: //twitter.com/marketsreports  

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts 

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml


Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
E-mail: sales@reportsandreports.com

SOURCE ReportsnReports